Lucentis' main patents are not due to expire ... intervals between dosing - an attractive proposition for patients as injections need to be administered into the eye - but has been affected ...

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This ...

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...

The implant is refillable and about the size of a grain of rice, continuously delivering ranibizumab over a period of months. The need for frequent injections with Lucentis and other wet AMD ...

Historically, the most common treatment for wet macular degeneration (wAMD) involved anti-vascular endothelial growth factor (VEGF) injections, such as Avastin, Lucentis, and Eylea. These drugs work ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Advancements include extended injection protocols that are the result of longer durations of action for recently approved therapies and the Port Delivery System with ranibizumab—a sustained drug ...